RCM
RA Capital Management Portfolio holdings
AUM
$9.76B
1-Year Est. Return
103.63%
This Fund
S&P 500
1 Year Est. Return
+103.63%
AUM
$8.12B
AUM Growth
+$2.18B
(+37%)
Holding
78
Top Buys
| 1 | +$98.6M | |
| 2 | +$57.4M | |
| 3 | +$55.6M | |
| 4 |
LBRX
LB Pharmaceuticals
LBRX
|
+$28.2M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$25.4M |
Top Sells
| 1 | +$92.5M | |
| 2 | +$48.1M | |
| 3 | +$40.6M | |
| 4 |
Enliven Therapeutics
ELVN
|
+$17M |
| 5 |
HNGE
Hinge Health
HNGE
|
+$15.5M |
Sector Composition
| 1 | Healthcare | 99.83% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMDA
76
Omada Health Inc
OMDA
$711M
| – | – |
-400,000
|
|
||
77
Protara Therapeutics
TARA
$341M
| – | – |
-1,039,295
|
|
||
|
TRML
78
DELISTED
Tourmaline Bio
TRML
| – | – |
-2,538,925
|
|